The successful story of PARP inhibitors in BRCA-deficient advanced breast and ovarian cancer has led to further investigation of their efficacy in prostate cancer, pancreatic and biliary tract malignancies, glioblastoma, and lung cancer. Here, PARP1 is linked to ovarian carcinoma.